The impact of cell proliferation markers and p53 mutation status on prognosis of non-metastatic colon cancer

2014 ◽  
Vol 109 (7) ◽  
pp. 665-675 ◽  
Author(s):  
Lutfiye Demir ◽  
Nese Ekinci ◽  
Cigdem Erten ◽  
Isil Somali ◽  
Alper Can ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cell Proliferation ◽  
P53 Mutation ◽  
Metastatic Colon Cancer ◽  
Proliferation Markers ◽  
Mutation Status ◽  
The Impact

A National Cancer Database (NCDB) analysis of the impact of nonmetastatic colon cancer sidedness on survival.

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 139-139
Author(s):  
Deven Patel ◽  
Timothy DiPeri ◽  
Brian Cox ◽  
Andrew Eugene Hendifar ◽  
Arsen Osipov ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Logistic Regression ◽  
Adjuvant Chemotherapy ◽  
Large Population ◽  
Stage I ◽  
Prognostic Impact ◽  
Metastatic Colon Cancer ◽  
Prognostic Features ◽  
Binomial Logistic Regression ◽  
The Impact

139 Background: Differences in embryological origin and tumor biology distinguish right-sided colon cancer (RCC) from left-sided colon cancer (LCC). Previous studies characterizing the prognostic impact of colon cancer laterality on clinical outcomes in non-metastatic colon cancer have been conflicting, thus closer examination is needed. Methods: Using the NCDB, patients with stage I-III colon cancer between 2004-2014 were stratified according to tumor location; RCC vs. LCC. Patient (pt) and tumor characteristics were compared in univariate analysis, survival (OS) was estimated by Kaplan-Meier (KM) curves and Cox proportional hazards modeling. Binomial logistic regression analysis was utilized to identify variables associated with colon cancer laterality. Results: Of the 342,735 pts who met inclusion criteria, 210,343 (61.4%) were diagnosed with RCC, and 132,392 (38.6%) with LCC. Pts with RCC were older (mean 71.6 vs. 66.4 years, p< 0.001) and predominantly female (65% vs. 35%, p< 0.001) compared to those with LCC. A trend towards poorer OS was seen in pts with RCC (mean 91.0 mos [95% CI: 90.2-91.8]) compared to LCC (112.2 mos [95% CI: 110.9-113.6]) in unadjusted analysis. On Cox multivariable adjusted analyses there was a significant but minimal impact on OS and laterality (hazard ratio or HR [LCC as ref] 0.978, 95% CI 0.967-0.989 p< 0.0001). Multiple unadjusted KM survival analyses showed RCC with T4 disease, high-grade, LVI/PNI, positive margins, N0-N2 disease, tumor deposits, and receipt of adjuvant chemotherapy had poorer OS than those features in LCC (all p < 0.0001). Binomial logistic regression showed RCCs were significantly more likely to be higher grade (odds ratio or OR 2.024) and MSI-H (OR 2.010) with trends (nonsignificant) towards more likely having N1-2 positive disease, LVI, less receipt of adjuvant chemotherapy, and fewer tumor deposits. Conclusions: The impact of sidedness on prognosis in stage I-III colon cancer is complex. In this large, population-based study, RCC tends to be associated with more adverse prognostic features than LCC. More investigation into the biologic differences between RCC and LCC is warranted and how they impact phenotype and survival.

The Impact of KRAS Mutation on the Presentation and Prognosis of Non-Metastatic Colon Cancer: an Analysis from the National Cancer Database

2020 ◽  
Vol 24 (6) ◽  
pp. 1402-1410 ◽  
Author(s):  
Aaron Scott ◽  
Paolo Goffredo ◽  
Timothy Ginader ◽  
Jennifer Hrabe ◽  
Irena Gribovskaja-Rupp ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Kras Mutation ◽  
Metastatic Colon Cancer ◽  
National Cancer Database ◽  
The Impact

scholarly journals 941 – The Impact of Kras Mutation on the Presentation and Prognosis of Non-Metastatic Colon Cancer: An Analysis from the National Cancer Database

2019 ◽  
Vol 156 (6) ◽  
pp. S-1421-S-1422
Author(s):  
Paolo Goffredo ◽  
Xiang Gao ◽  
Timothy Ginader ◽  
Jennifer Hrabe ◽  
Irena Gribovskaja-Rupp ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Kras Mutation ◽  
Metastatic Colon Cancer ◽  
National Cancer Database ◽  
The Impact

The impact of Aldehyde dehydrogenase 1 expression on prognosis for metastatic colon cancer

2014 ◽  
Vol 192 (1) ◽  
pp. 82-89 ◽  
Author(s):  
Timothy L. Fitzgerald ◽  
Swathi Rangan ◽  
Larry Dobbs ◽  
Shane Starr ◽  
George Sigounas
Keyword(s):  
Colon Cancer ◽  
Aldehyde Dehydrogenase ◽  
Metastatic Colon Cancer ◽  
Aldehyde Dehydrogenase 1 ◽  
The Impact

scholarly journals The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer

2017 ◽  
Vol 25 (2) ◽  
pp. 431-438 ◽  
Author(s):  
John M. Creasy ◽  
Eran Sadot ◽  
Bas Groot Koerkamp ◽  
Joanne F. Chou ◽  
Mithat Gonen ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Hepatic Resection ◽  
Primary Tumor ◽  
Tumor Location ◽  
Metastatic Colon Cancer ◽  
Term Survival ◽  
Long Term Survival ◽  
Primary Tumor Location ◽  
The Impact

Impacts of microRNA-215 on cell proliferation and chemotherapy resistance in colon cancer and osteosarcoma

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 2542-2542
Author(s):  
J. Ju ◽  
B. Song ◽  
Y. Wang
Keyword(s):  
Cell Cycle ◽  
Stem Cells ◽  
Colon Cancer ◽  
Cell Proliferation ◽  
Cancer Stem Cells ◽  
Cell Lines ◽  
Chemotherapy Resistance ◽  
Osteosarcoma Cell ◽  
Colon Cancer Stem Cells ◽  
The Impact

2542 Background: Translational control plays a key role in resistance to anti-cancer drug treatment. MicroRNAs regulate gene expression at the post-transcriptional level, mainly by interacting with 3'-UTR of their mRNA targets. Methods: miR-215 was ectopically expressed by transient transfection in both human colon cancer cell lines and osteosarcoma cell lines. The impact of miR-215 on cell proliferation, cell cycle control, chemosensitivity and down stream targets were characterized. The expression of miR-215 in colorectal cancer specimens and normal adjacent tissues was quantified by real time-qRT-PCR analysis. Results: In this study, we discovered that miR-215 down-regulates the expression of both dihydrofolate reductase (DHFR) and thymidylate synthase (TS), two of the most important chemotherapeutic targets, in human osteosarcoma U-2 OS and colon cancer HCT-116 (wt-p53) cell lines. Cells with elevated miR-215 expression are more resistant to DHFR inhibitor methotrexate (MTX) or TS inhibitor Tomudex (TDX) treatment. Ectopically over-expressing miR-215 triggers reduced cell proliferation and increased G2 arrest, at least in part, through the induction of p53 and p21. miR-215 transfected cells with reduced proliferating phenotype were resist to MTX or TDX treatment due to deceased cell cycle in S phase. The expression of endogeneous miR-215 was highly elevated in CD133+/HI CD44+/HI colon cancer stem cells compared to CD133- CD44- colon cancer cells, suggesting that tumor stem cells may be avoiding cellular and DNA damage caused by chemotherapy with a reduced proliferating phenotype mediated by certain miRNAs such as miR-215. The elevated expression of miR-215 in colon cancer stem cells with slow proliferation rate and resistance to chemotherapy further supports the role of miR-215 in cell proliferation and chemotherapy resistance. Conclusions: miR-215 may have a unique potential as a novel therapeutic target and biomarker candidate in cancer. No significant financial relationships to disclose.

Quantitative MR imaging biomarkers of tumor heterogeneity predict prognosis in metastatic colorectal lesions.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15121-e15121 ◽  
Author(s):  
Dania Daye ◽  
Sophia C. Kamran ◽  
Azadeh Tabari ◽  
Mark Michalski ◽  
Jeffrey W. Clark ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Kras Mutation ◽  
Tumor Heterogeneity ◽  
Patient Survival ◽  
Imaging Biomarkers ◽  
Survival Prediction ◽  
Metastatic Colon Cancer ◽  
Mutation Status ◽  
Kras Mutation Status

e15121 Background: Intra-tumor heterogeneity is an independent determinant of patient survival outcomes in several tumor subtypes. Spatial variations in tumor enhancement on MRI is a macroscopic imaging marker of tumor heterogeneity. The goal of this study is to evaluate the potential role of MRI-based enhancement heterogeneity measures as predictors of survival in patients with metastatic colorectal cancer. Methods: We retrospectively analyzed T1-weighted contrast-enhanced MRI images of metastatic hepatic lesions in 41 patients (mean age 57.2 ±14.2 years) who were diagnosed with stage IV colorectal cancer between 2007 and 2013. Tumor Kras mutation status and patient survival data for up to 95 months was available for all patients. The largest metastatic hepatic lesion was identified by a radiologist and manually segmented. 14 Haralick texture features were extracted from each lesion. Cox proportional hazards regression analysis was used to assess the association between the enhancement heterogeneity measures and patient survival, with adjustment for Kras mutation status as a potential confounder. Backward stepwise feature selection was performed using p > 0.1 (Wald test) to select for statistically significant features. Results:Mean survival time was 39±3.9 months for the study population (51±4.1 months for Kras-wildtype and 37±5.1 for Kras-mutants). 68% of the patients had left-sided colon cancer; 21% had concurrent pulmonary metastases and 0.5% had concurrent brain metastasis. 61%, 27% and 12% of patients were on Flofox, Folfiri or other chemotherapeutic regimen, respectively. Texture matrix homogeneity (HR > 10; p = 0.016), inverse difference moment (HR < 0.1; p = 0.020), entropy (HR < 0.1; p = 0.033) and standard deviation (HR > 10; p = 0.006) exhibited significant independent association with patient survival. With the exception of entropy, these features maintained significant contribution to survival prediction independent of Kras mutation status. Conclusions: MRI-based quantitativeintra-metastasis heterogeneity measures are associated with patient survival and may add information beyond genetic mutation status to optimize prognosis prediction in metastatic colon cancer.

Sign in / Sign up

Export Citation Format

Share Document